Discounted Cash Flow (DCF) Analysis Levered

CytomX Therapeutics, Inc. (CTMX)

$2.65

+0.20 (+8.16%)
All numbers are in Millions, Currency in USD
Stock DCF: -21.68 | 2.65 | overvalue

Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 59.5057.49100.3669.5753.1655.4157.7660.2062.7565.41
Revenue (%)
Operating Cash Flow -75.52-140.485.26-119.03-110.79-82.62-86.12-89.76-93.56-97.52
Operating Cash Flow (%)
Capital Expenditure -3.79-3.50-2.31-1.61-1.74-2.25-2.35-2.45-2.55-2.66
Capital Expenditure (%)
Free Cash Flow -79.31-143.982.95-120.64-112.53-84.88-88.47-92.21-96.12-100.18

Weighted Average Cost Of Capital

Share price $ 2.65
Beta 0.835
Diluted Shares Outstanding 65.74
Cost of Debt
Tax Rate 2.03
After-tax Cost of Debt 4.07%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.100
Total Debt 18.06
Total Equity 174.21
Total Capital 192.27
Debt Weighting 9.39
Equity Weighting 90.61
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 59.5057.49100.3669.5753.1655.4157.7660.2062.7565.41
Operating Cash Flow -75.52-140.485.26-119.03-110.79-82.62-86.12-89.76-93.56-97.52
Capital Expenditure -3.79-3.50-2.31-1.61-1.74-2.25-2.35-2.45-2.55-2.66
Free Cash Flow -79.31-143.982.95-120.64-112.53-84.88-88.47-92.21-96.12-100.18
WACC
PV LFCF -78.79-76.24-73.77-71.39-69.07
SUM PV LFCF -369.27

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.72
Free cash flow (t + 1) -102.19
Terminal Value -1,786.48
Present Value of Terminal Value -1,231.73

Intrinsic Value

Enterprise Value -1,601
Net Debt -175.59
Equity Value -1,425.41
Shares Outstanding 65.74
Equity Value Per Share -21.68